a:5:{s:8:"template";s:7025:"<!DOCTYPE html>
<html lang="en"> 
<head>
<title>{{ keyword }}</title>
<meta charset="utf-8">
<meta content="width=device-width, initial-scale=1.0" name="viewport">
<link href="https://fonts.googleapis.com/css?family=Open+Sans%3A300italic%2C400%2C400italic%2C600%2C600italic%2C700%7CRoboto%3A300%2C400%2C400italic%2C500%2C500italic%2C700%2C900&amp;ver=9.8" id="google-fonts-style-css" media="all" rel="stylesheet" type="text/css">
</head>
<style rel="stylesheet" type="text/css">.has-drop-cap:not(:focus):first-letter{float:left;font-size:8.4em;line-height:.68;font-weight:100;margin:.05em .1em 0 0;text-transform:uppercase;font-style:normal}.has-drop-cap:not(:focus):after{content:"";display:table;clear:both;padding-top:14px} @font-face{font-family:'Open Sans';font-style:italic;font-weight:300;src:local('Open Sans Light Italic'),local('OpenSans-LightItalic'),url(https://fonts.gstatic.com/s/opensans/v17/memnYaGs126MiZpBA-UFUKWyV9hrIqY.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:italic;font-weight:400;src:local('Open Sans Italic'),local('OpenSans-Italic'),url(https://fonts.gstatic.com/s/opensans/v17/mem6YaGs126MiZpBA-UFUK0Zdcg.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:italic;font-weight:600;src:local('Open Sans SemiBold Italic'),local('OpenSans-SemiBoldItalic'),url(https://fonts.gstatic.com/s/opensans/v17/memnYaGs126MiZpBA-UFUKXGUdhrIqY.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:normal;font-weight:400;src:local('Open Sans Regular'),local('OpenSans-Regular'),url(https://fonts.gstatic.com/s/opensans/v17/mem8YaGs126MiZpBA-UFVZ0e.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:normal;font-weight:600;src:local('Open Sans SemiBold'),local('OpenSans-SemiBold'),url(https://fonts.gstatic.com/s/opensans/v17/mem5YaGs126MiZpBA-UNirkOUuhs.ttf) format('truetype')}@font-face{font-family:'Open Sans';font-style:normal;font-weight:700;src:local('Open Sans Bold'),local('OpenSans-Bold'),url(https://fonts.gstatic.com/s/opensans/v17/mem5YaGs126MiZpBA-UN7rgOUuhs.ttf) format('truetype')} 
html{font-family:sans-serif;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%}body{margin:0}body{visibility:visible!important}*{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}:after,:before{-webkit-box-sizing:border-box;-moz-box-sizing:border-box;box-sizing:border-box}.td-container{width:1068px;margin-right:auto;margin-left:auto}.td-container:after,.td-container:before{display:table;content:'';line-height:0}.td-container:after{clear:both}.td-pb-row{margin-right:-24px;margin-left:-24px;position:relative}.td-pb-row:after,.td-pb-row:before{display:table;content:''}.td-pb-row:after{clear:both}.td-pb-row [class*=td-pb-span]{display:block;min-height:1px;float:left;padding-right:24px;padding-left:24px;position:relative}@media (min-width:1019px) and (max-width:1140px){.td-pb-row [class*=td-pb-span]{padding-right:20px;padding-left:20px}}@media (min-width:768px) and (max-width:1018px){.td-pb-row [class*=td-pb-span]{padding-right:14px;padding-left:14px}}@media (max-width:767px){.td-pb-row [class*=td-pb-span]{padding-right:0;padding-left:0;float:none;width:100%}}@media (min-width:1019px) and (max-width:1140px){.td-container{width:980px}.td-pb-row{margin-right:-20px;margin-left:-20px}}@media (min-width:768px) and (max-width:1018px){.td-container{width:740px}.td-pb-row{margin-right:-14px;margin-left:-14px}}@media (max-width:767px){.td-container{width:100%;padding-left:20px;padding-right:20px}.td-pb-row{width:100%;margin-left:0;margin-right:0}}.td-header-wrap{position:relative;z-index:2000}.td-header-row{font-family:'Open Sans',arial,sans-serif}.td-header-row:after,.td-header-row:before{display:table;content:''}.td-header-row:after{clear:both}.td-header-row [class*=td-header-sp]{display:block;min-height:1px;float:left;padding-right:24px;padding-left:24px}@media (min-width:1019px) and (max-width:1140px){.td-header-row [class*=td-header-sp]{padding-right:20px;padding-left:20px}}@media (min-width:768px) and (max-width:1018px){.td-header-row [class*=td-header-sp]{padding-right:14px;padding-left:14px}}@media (max-width:767px){.td-header-row [class*=td-header-sp]{padding-right:0;padding-left:0;float:none;width:100%}}#td-outer-wrap{overflow:hidden}@media (max-width:767px){#td-outer-wrap{margin:auto;width:100%;-webkit-transition:transform .7s ease;-moz-transition:transform .7s ease;-o-transition:transform .7s ease;transition:transform .7s ease;-webkit-transform-origin:50% 200px 0;-moz-transform-origin:50% 200px 0;-o-transform-origin:50% 200px 0;transform-origin:50% 200px 0}}body{font-family:Verdana,Geneva,sans-serif;font-size:14px;line-height:21px}h1{font-family:Roboto,sans-serif;color:#111;font-weight:400;margin:6px 0}h1{font-size:32px;line-height:40px;margin-top:33px;margin-bottom:23px} @media print{body,html{background-color:#fff;color:#000;margin:0;padding:0}body{width:80%;margin-left:auto;margin-right:auto;zoom:80%}h1{page-break-after:avoid}}.td-sub-footer-container{background-color:#0d0d0d;color:#ccc;font-size:12px;font-family:'Open Sans',arial,sans-serif}@media (max-width:767px){.td-sub-footer-container{text-align:center;padding:6px 0}}.td-sub-footer-copy{line-height:20px;margin-top:8px;margin-bottom:8px}@media (max-width:767px){.td-sub-footer-copy{float:none!important}}.td-header-top-menu-full{position:relative;z-index:9999}@media (max-width:767px){.td-header-top-menu-full{display:none}}@-moz-document url-prefix(){}.td-header-style-6 .td-header-top-menu-full{background-color:#f9f9f9}.td-header-style-6 .td-header-top-menu-full .td-header-top-menu{color:#000}.td-header-top-menu{color:#fff;font-size:11px}@media (min-width:1019px) and (max-width:1140px){.td-header-top-menu{overflow:visible}}.td-header-sp-top-menu{line-height:28px;padding:0!important;z-index:1000;float:left}@media (max-width:767px){.td-header-sp-top-menu{display:none!important}}@-moz-document url-prefix(){}@-moz-document url-prefix(){}@-moz-document url-prefix(){} .td-container-wrap{background-color:#fff;margin-left:auto;margin-right:auto}.td_stretch_content{width:100%!important}@media (min-width:768px){.td_stretch_content .td-container{width:100%!important;padding-left:20px;padding-right:20px}}.td-sub-footer-container{background-color:#0d0d0d;color:#ccc;font-size:12px;font-family:'Open Sans',arial,sans-serif}@media (max-width:767px){.td-sub-footer-container{text-align:center;padding:6px 0}}.td-sub-footer-copy{line-height:20px;margin-top:8px;margin-bottom:8px}@media (max-width:767px){.td-sub-footer-copy{float:none!important}}.td-black{background-color:#1a1a1a;color:#eee}.td-black h1{color:#fff}</style>
<body class="td-black">
<h1>{{ keyword }}</h1>
<div class="td-theme-wrap" id="td-outer-wrap">
{{ text }}
<br>
{{ links }}
<div class="td-sub-footer-container td-container-wrap td_stretch_content">
<div class="td-container">
<div class="td-pb-row">
<div class="td-pb-span td-sub-footer-copy">
{{ keyword }} 2022
</div>
</div>
</div>
</div>
</div>
</body>
</html>";s:4:"text";s:36566:"Given these favorable data, chemotherapy-free ATRA plus RIF regimen was investigated in a multicenter, noninferiority clinical trial [76]. The treatment of acute promyelocytic leukemia (APL) has evolved rapidly in the past two decades after the introduction of highly active drugs, including tretinoin (all- trans -retinoic acid) and arsenic trioxide. 2015;2:e35766. Huang ME, Ye YC, Chen SR, Chai JR, Lu JX, Zhoa L, et al. Acute Promyelocytic Leukemia (APL): Diagnosis and Treatment - Episode 5 . 2013;31:421521. As compared with qualitative RT-PCR tests, RQ-PCR is less prone to contamination, allows for a better assessment of disease response kinetics, and enables better identification of poor-quality samples that could result in false-negatives.40 A longitudinal comparative RQ-PCR study of paired BM and PB samples for PML/RARA monitoring showed an earlier detection of molecular relapse in BM.43 These data suggest that BM sampling remains the preferred approach.     (November 01, 2018)
 2020;105:156774. If you need to talk, we&#x27;ll listen. Optimal treatment strategies for high-risk acute promyelocytic leukemia. Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy.                 FOIA In a pilot study from Hong Kong, 62 patients with newly diagnosed APL received ATRA+oral ATO (10mg/day) induction (patients aged <70 received DNR as well), and all achieved CR (Table 2). Click below to read more about APL treatments: All-trans retinoic acid (ATRA), also called tretinoin (Vesanoid), is given orally. Signs, symptoms and complications of APL result from the overproduction of promyelocytes and the underproduction of healthy blood cells.  2008;19:37990. APL was classified as AML-M3 in the older French-American-British (FAB) classification system and is currently classified as acute promyelocytic leukemia with t (15;17) (q24.1;q21.1); PML-RARA in the World Health Organization classification system [ 1 ]. 02/03/2003. Its rapidly increasing propensity for bleeding means that APL needs to be recognized and treated quickly. Although patients in both arms achieved similar CR rates after induction (72% vs. 69%), the 3-year disease-free survival (DFS) and overall survival (OS) rates were significantly superior in ATRA arm than in the chemotherapy-alone arm, 67 vs. 32%, and 67 vs. 50%, respectively (Table 1). concept Search across key concepts extracted from titles and abstracts matching text Search across indexed text content in Pure, such as names, titles, descriptions etc. APL must be considered at the top of the differential diagnosis in patients with suspected leukemia and appropriate presentation, and every possible effort should be made to rule it out promptly (Fig. The Macmillan Support Line is a free and confidential phone service for people living and affected by cancer. Here, we present our deliberations leading to our consensus recommendations along with some of the alternatives used by others (Table 2). Br J Haematol.  randomized 109 patients with newly diagnosed APL (lower risk) to receive ATRA plus RIF or IV ATO until CR followed by ATRA plus RIF or IV ATO consolidation for seven months without any maintenance therapy (Table 2). 2004;103:123743. 2011;118:83. 1999;94:1192200. Treatment of Acute Promyelocytic Leukemia in Adults. About Expert Rev Hematol. Accessed April 28, 2021. . A recent update of this trial, analyzing an extended series of patients with a median follow-up of 41 months, showed that the event-free and overall survival advantages of ATRA plus ATO significantly increased over time, together with a statistically significant lower cumulative incidence of relapse rate in the ATO plus ATRA cohort, therefore also indicating greater efficacy of the latter regimen.22. ATRA, arsenic trioxide (ATO), and gemtuzumab ozogamicin (GO) is safe and highly effective in patients with previously untreated high-risk acute promyelocytic leukemia (APL): final results of the SWOG/Alliance/ECOG S0535 trial. Best Pract Res Clin Haematol. ND, not determined; Ref., reference citation number. We watch closely for toxicities, including prolongation of the QT interval on electrocardiogram, liver function test abnormalities, GI symptoms (nausea, vomiting, or abdominal pain), and neuropathy. J Clin Oncol. Less commonly, thrombotic complications may dominate the clinical presentation. Proc Natl Acad Sci USA. In the UK study, the 4-year OS rate was 89% in patients with the high-risk disease [44]. APS is a systemic autoimmune disease defined by thrombotic or obstetrical events that occur in patients with persistent antiphospholipid antibodies. Developing a simplified algorithm that focused on prevention of early deaths, they were able to reduce early mortality to 8.5%. Based on recent studies,57-62 autologous HSCT should be considered the first choice for eligible patients achieving second molecular remission. Aribi A, Kantarjian HM, Estey EH, Koller CA, Thomas DA, Kornblau SM, et al. 1986;67:55961. Treatment with ATRA should be started immediately when a diagnosis of APL is suspected, 1.6. 2018;59(6):725-734. doi: 10.11406/rinketsu.59.725. Overall, 510% of the patients with APL develop relapsed and/or refractory (R/R) disease. Acute promyelocytic leukemia (APL) is one of several subtypes of acute myeloid leukemia, a blood cancer that originates in a person&#x27;s bone marrow. Maintenance therapy with ATRA or 6-MP/methotrexate (MTX) significantly decreased relapse rates and improved survival. Low- and intermediate-risk APL (differentiated by platelet counts above and below 40109/L) also referred to as standard-risk APL are defined by a WBC count of equal to or less than 10,000/L. 1973;41:48996. The combination of ATRA and idarubicin is known as AIDA. OR. Ten of 12 patients treated for newly diagnosed APL achieved a complete remission. Blood. Treatment. Blood. RQ-PCR is currently the standard method for molecular monitoring in APL. These NCCN Guidelines Insights focus on recent select updates to the NCCN Guidelines, including familial genetic alterations in AML, postinduction or postremission treatment strategies in low-risk acute promyelocytic leukemia or favorable-risk AML, principles surrounding the use of venetoclax-based therapies, and considerations for patients who . In the early 1980s, all-trans-retinoic acid (ATRA) was shown to induce functional and morphological maturation in APL cells [10, 11]. In patients presenting in the first trimester and not wishing to have a termination of pregnancy, induction therapy with daunorubicin alone can be offered, 3.9. Zhu HH, Wu DP, Du X, Zhang X, Liu L, Ma J, et al. WBC count at presentation is a useful prognostic factor segregating patients into low-, intermediate-, and high-risk categories. Au WY, Tam S, Fong BM, Kwong YL.  However, a recent NCRI report questions the role of transplantation, at least in patients achieving molecular remission with ATO and ATRA who do not have CNS disease at relapse and who have received a full course of consolidation with ATO.23 Patients failing to achieve molecular remission are candidates for allogeneic HSCT.      PubMed 1981;57:10004.  Leukemia. Ads L, Chevret S, Raffoux E, de Botton S, Guerci A, Pigneux A, et al. Montesinos P, Rayn C, et al. N Engl J Med. served on speakers bureaus for, and received honoraria from, Novartis, Janssen, Roche, and AbbVie. If further testing rules out APL, ATRA can be discontinued with zero or minimal toxicity. Cytoreductive chemotherapy should be started without delay, even if the molecular results are still pending:  For patients to be treated with ATRA + chemotherapy, idarubicin or daunorubicin alone or combined with cytarabine should be given,  For patients to be treated with ATRA + ATO, cytoreduction can be done with idarubicin (12 mg/m, 1.11. These promising results have led to a national intergroup clinical trial (NCT#03253848) Simplified Patient Care Strategy in Decreasing Early Death in Patients With Acute Promyelocytic Leukemia that is currently in progress. Zhu HH, Huang XJ. These morphologic, cytogenetic, and molecular findings are not indicative of therapy failure and do not justify any treatment modification. Comanagement strategy between academic institutions and community practices to reduce induction mortality in acute promyelocytic leukemia. Early haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute promyelocytic leukaemia.          ASCO Connection     September 25, 2018.     CAS RIF has been approved and is being used for APL therapy in China.                  HHS Vulnerability Disclosure, Help In an effort to standardize our approach to the treatment of newly diagnosed APL, we sought to develop a set of treatment recommendations at our institution. 2009;27:50410.   Heuser M, Ofran Y, Boissel N, et al. On the basis of our clinical experience, we recommend against the use of prophylactic corticosteroids and instead recommend the prompt administration of intravenous dexamethasone 10 mg every 12 hours at the first signs or symptoms of differentiation syndrome. Arsenic trioxide during consolidation for patients with previously untreated low/intermediate risk acute promyelocytic leukaemia may eliminate the need for maintenance therapy. Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial. Ann Oncol. Changes to the European Guidelines for Treatment of APL January 17, 2017 EP. Many induction and consolidation regimens for APL include arsenic trioxide in combination with all-trans. (ATRA) and arsenic trioxide (ATRA/arsenic trioxide) for the treatment of acute promyelocytic leukemia (APL) has been associated with substantial improvements in outcomes, and APL is now the most curable subtype of . Patients achieving second CR should receive intensification with HSCT or chemotherapy, if possible, 5.4. 2017;129:127583.      PubMed Zhao WL, Chen SJ, Shen Y, Xu L, Cai X, Chen GQ, et al. These classifications are used in Tables 1-3 and 5. Of importance, randomized prospective data examining the value of prophylactic intrathecal chemotherapy are not available. APL results from a balanced translocation, commonly t(15;17) (q22;q12-21), which leads to the fusion of the promyelocytic leukemia (PML) gene with the retinoic acid receptor alpha (RARA) gene [2]. Indeed, ATO was given at lower doses on a daily basis in the Italian-German trial whereas the NCRI study used the higher dose administered 2 or 3 days per week.       Disclaimer, National Library of Medicine Epub 2008 Sep 23. Kwong YL, Au WY, Chim CS, Pang A, Suen C, Liang R. Arsenic trioxide- and idarubicin-induced remissions in relapsed acute promyelocytic leukaemia: clinicopathological and molecular features of a pilot study. 2009 Feb 26;113(9):1875-91. doi: 10.1182/blood-2008-04-150250. Blood. It is clinically distinguished from other AML subtypes by life-threatening bleeding disorders. The drug is typically administered during weeks 1 to 4 at 0.15 mg/kg/d for 5 days per week.4,8,20. The European APL Group. GUIDELINE QUESTIONS . However, patients with APL may need specific kinds of supportive care. Comparable CR rates have been reported using either ATRA plus daunorubicin and cytarabine or ATRA plus idarubicin alone, with no apparent advantage observed by adding other cytotoxic agents. Combination therapy with arsenic trioxide, all-trans retinoic acid, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia. ATO has the propensity to prolong the corrected QT (QTc) interval, placing the patient at risk for dangerous arrhythmias; therefore, we recommend obtaining a baseline ECG before initiation of therapy, along with monitoring serum electrolytes daily and QTc interval at least weekly during induction. 1991;4:23948.     CAS J Clin Oncol. Therapy-related acute promyelocytic leukemia. Multicenter randomized trial of arsenic trioxide and Realgar-Indigo naturalis formula in pediatric patients with acute promyelocytic leukemia: Interim results of the SCCLG-APL clinical study. Ten years later, a European LeukemiaNet expert panel has reviewed the recent advances in the management of APL in both frontline and relapse settings in order to develop updated evidence- and expert opinion-based recommendations on the management of this disease. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. The levels of evidence and grading of recommendations were those defined in the General Guidelines for Methodologies on Research and Evaluation of Traditional Medicine (Appendix).7 We emphasize changes based on new data from 2009. The management of a cerebral stroke or major thrombosis in the context of the coagulopathy remains challenging and potentially threatening with few data available. Dayyani F, Kantarjian H, O'Brien S, Pierce S, Jones D, Faderl S, et al.                 Farhad Ravandi. Best Pract Res Clin Haematol. Nat Rev Cancer. Curr Opin Hematol. In the majority of such cases, a molecular analysis nevertheless reveals an underlying PMLRARA fusion transcript formed as a result of cytogenetically cryptic or complex insertion events [2]. In a phase II study, 35 patients with R/R APL were treated with ATO, followed by autologous stem cell transplantation. Dyspnea, pulmonary infiltrates, pleural effusion, fever, weight gain, peripheral edema, hypotension, and acute renal failure are the hallmarks of this syndrome. Clinical signs of coagulopathy vary from mild mucocutaneous bleeding to severe intracranial or pulmonary hemorrhage. Association between serum albumin and 60-day mortality in Chinese Hakka patients with non-APL acute myeloid leukemia: a retrospective cohort study. Blood 2004; 104:3490. The 5-year EFS, DFS, and OS for 54 high-risk patients were 81%, 89%, and 86%, respectively.7 A similar regimen was also used in 28 patients with high-risk APL in the UK AML17 trial; however, GO was used at 6 mg/m2 instead of 9 mg/m2. Blood. This guideline will not recapitulate these clinical trials but is a general guide to treatment strategies for new and relapsed patients.         Contact Us In prospective ATRA+ATO clinical trials performed by MD Anderson and UK AML working group, GO was administered during induction for patients with WBC greater than 10,000 at diagnosis [40, 44, 46]. Leuk Lymphoma. The addition of gemtuzumab ozogamicin to induction chemotherapy for AML improves disease free survival without extra toxicity: preliminary analysis of 1115 patients in the MRC AML15 trial.         Institutions An alternative would be to divide the GO dose into doses of 3 mg/m2 administered on days 1, 4, and 7 of induction, using the schedule pioneered by the French ALFA group when treating acute myeloid leukemia in older patients.28. MRD positivity clearly exists when RT-PCR is positive using low sensitive methods (threshold detection roughly 1 cell in 104) at 2 consecutive time points at least 4 weeks apart. ATO associated neutropenia may occur as a result of delayed bone marrow evaluation and unnecessarily prolonged ATO therapy. Previous ELN recommendations for the management of relapse were entirely focused on patients who relapsed following ATRA plus chemotherapy as first-line treatment.4 Here, 2 independent retrospective studies reported that early treatment intervention in patients with molecular relapse affords a better outcome than treatment only at hematologic relapse.55,56 Hence the recommendation (unchanged since 2009) is to promptly start preemptive therapy in order to prevent hematologic relapse. Eligible patients should be offered entry into a clinical trial, 2.2. With ATRA monotherapy, the duration of response was usually short, 36 months. Invasive procedures such as central venous catheterization, lumbar puncture, and bronchoscopy should be avoided at diagnosis and during initial treatment as long as the coagulopathy is active. A presentation WBC count greater than 10,000/L represents high-risk APL. As a general rule, treatment of patients with ATRA-sensitive variants should include this agent in combination with anthracycline-based chemotherapy, whereas in those with ATRA-resistant variants, the addition of ATRA is less attractive and management should consist of AML-like approaches. Patients with tAPL should be treated like those with de novo APL, but modifications may be necessary taking into account cardiac toxicity and prior anthracycline exposure, Sensitive, in vitro sensitive in 1 of 2 cases, 5.1. LTC Guidelines/Policy Letters GMC/Two Plan Letter. Induction therapy starts immediately after diagnosis with the goals to kill as many APL cells as possible, bring blood cell counts to normal levels, and decrease APL-related symptoms.  Entry of elemental arsenic into the central nervous system in patients with acute promyelocytic leukemia during arsenic trioxide treatment. N Engl J Med. Prophylactic corticosteroids to prevent differentiation syndrome have been used in some studies but the value of the use of steroids remains unclear. APL treatment has three phases: Induction The goals of induction are to kill APL cells, restore normal blood counts, and relieve symptoms. Chamoun K, Kantarjian HM, Wang X, Naqvi K, Aung F, Garcia-Manero G, et al. In both clinical trials, patients continued ATRA+ATO during consolidation without GO, and none of the patients received maintenance therapy. These studies disclosed the presence at diagnosis of several gene mutations in addition to PML/RARA, together with an increased rate of mutations, including point mutations affecting the RARA and/or PML moieties of the hybrid oncoprotein in relapsed samples.12,13 Such additional aberrations had no impact on prognosis and their detection is therefore not recommended in the routine evaluation of patients outside of clinical trials. The main APL treatment is a differentiating agent. 3). A rapid confirmation of genetic diagnosis is mandatory and should be performed, if possible, on bone marrow (BM) samples. Side effects may be caused by the drug type and dose used, length of treatment and the patients overall health. Burnett AK, Russell NH, Hills RK, Bowen D, Kell J, Knapper S, et al. Consolidation cycles consisted of either DNR+ARA-C (age <70 years old) or ATRA monotherapy (age 70 years old), with all receiving ATRA maintenance therapy [70]. Jcomo RH, Melo RA, Souto FR, de Mattos ER, de Oliveira CT, Fagundes EM, et al. The supportive measures recommended to treat the coagulopathy have not changed during the last decade. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. Considering these epidemiological data, an obese Hispanic patient (in her/his forties) may fit an APL stereotype. Regarding the duration of ATO during induction therapy, in the NCRI trial, the drug was given at a dose of 0.3 mg/kg on days 1 to 5 in week 1 followed by 0.25 mg/kg twice weekly for 7 weeks, whereas in the Italian-German trial, the drug was given at a dose of 0.15 mg/kg daily until CR.   Elderly patients in good clinical condition treated with chemotherapy-based regimens should be managed with a treatment approach similar to that used in younger patients, but slightly attenuated in dose intensity; although the experience with chemotherapy-free approaches in this setting is very limited, it seems reasonable to follow a similar strategy for patients with nonhigh-risk APL, 3.2. For patients with a WBC count >10  10, 2.4. There are several types of anthracyclines; daunorubicin (Cerubidine) and idarubicin (Idamycin) are the drugs most commonly used in the treatment of APL, typically in combination with ATRA. APL is a potentially life-threatening disease; however, it is the most curable form of adult leukemia. APL can develop very quickly so you will start treatment straight away. In the era of ATO, maintenance therapy is no longer needed in APL. Study Design Go to Resource links provided by the National Library of Medicine Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando SM, Iacobelli S, et al. Blood. RIF has been commercialized and is commonly available in China, whereas it is not licensed elsewhere.             Cite this article. 2009;113:77583. APL 17-003 Treatment of Recoveries Made by the Managed Care Health Plan of Overpayments to Providers 03/30/2017 APL 17-004 Subcontractual Relationships and Delegation 04/18/2017 .  *Lower risk APL: ATRA+IDA or ATRA+GO **Higher risk: ATRA+IDA or ATRA+DNR+ARA-C.  Rinsho Ketsueki. In a phase I and II study of ATO in patients with relapsed APL, three of 10 patients died suddenly during treatmentall three were obese.24 Shen and colleagues25 demonstrated that, in 20 patients with relapsed APL, there was no difference in OS or RFS in patients who were treated with low-dose ATO (0.08 mg/kg) compared with standard-dose ATO (0.15 mg/kg). Because early treatment intervention in patients with evidence of MRD affords a better outcome than treatment in full-blown relapse, MRD monitoring of BM has been used in routine clinical practice for all patients. Clinicians must initiate ATRA treatment (on the earliest suspicion), diagnose promptly, and monitor vigorously during therapy to minimize expected complications of APL. These controversial issues include the optimal dose and schedule of both all-trans-retinoic acid and arsenic trioxide, the optimal regimen for high-risk APL, the need for intrathecal prophylaxis, the use of prophylactic corticosteroids, and the need for maintenance therapy after consolidation. Differentiation and cytokine release syndrome remains an important cause of morbidity and mortality during remission induction treatment of APL. Au WY, Tam S, Kwong YL. Download or order TheLeukemia& Lymphoma Society's free fact sheet, For information about the drugs mentioned on this page, visit.   In another randomized study, similar favorable outcomes with ATRA plus RIF regimen were reproduced in a pediatric population [77]. 2). As a consequence of the complex coagulopathy associated with APL, which reflects consumptive coagulation as well as primary and secondary fibrinolysis, intracerebral and pulmonary hemorrhages are the most frequent causes of death both prior to and shortly after treatment initiation. Unlike other subtypes of AML, there is no prognostic difference in therapy-related APL (1). Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, et al. This medicine is a form of the chemical arsenic.  All-trans-retinoic acid in acute promyelocytic leukemia. Already approved in China, oral arsenic therapy needs to be further explored in the United States and Europe. Cytotoxic Mechanism of Momilactones A and B against Acute Promyelocytic Leukemia and Multiple Myeloma Cell Lines. It is caused by a genetic change that is acquired over a person&#x27;s lifetime, usually involving a translocation between chromosomes 15 and 17.         JCO Oncology Practice         Cancer.Net, ASCO.org E.L. received honoraria from, and served on advisory boards for, Teva and Novartis. Supportive treatment should be continued during induction therapy until disappearance of all clinical and laboratory signs of the coagulopathy.  received honoraria from Celgene, Novartis, and Teva, and research support from Celgene, Janssen, Amgen, and Teva. For patients treated with conventional ATRA + chemotherapy approaches: maintenance therapy should be used for patients who have received an induction and consolidation treatment regimen wherein maintenance has shown a clinical benefit, 2.12. Day 1 (Cycle 1) OR Days 1-2 (Cycle 2): Daunorubicin 60mg/m 2 IV. 2015;168:64653. However, it is important to note that ATO dose schedules used in these phase III clinical trials were different: APL0406 used a ATO+ATRA schedule based on MDACC regimen [39] (ATO IV 0.15mg/kg/day daily until CR, and 0.15mg/kg/day five days/week for four weeks of consolidation cycles 14), AML17 (ATO IV 0.3mg/kg on days 15 of each cycle, and at 0.25mg/kg twice weekly in weeks 28 of cycle one and weeks 24 of cycles 25). Minimizing unnecessary procedures, such as central venous catheters, lumbar puncture, and leukapheresis, is also recommended. 2018;19:8719. Corticosteroids (10 mg of dexamethasone IV twice daily) should be started immediately at the earliest clinical suspicion of incipient APL differentiation syndrome; once the syndrome has resolved, steroids can be discontinued and ATO/ATRA recommenced, 1.14. 2018;131:29879. Anti-2-glycoprotein-I antibody (a2GPI) Higher levels of aCL and a2GPI (especially higher than 40 units) correspond to an increased risk of an aPL-related event; lower levels are clinically less important (especially levels lower than 20 units). NCCN guidelines for treatment by cancer type: acute myeloid leukemia. On the other hand, prolonged QTc and grade 3/4 hepatotoxicity is more common in ATRA+ATO than ATRA+chemotherapy, 13% vs. 0% (p<0.01), and 57% vs. 5% (p<0.01), respectively [41]. 1988;72:56772. Hispanic ethnicity and obesity have been reported as prevalent presentation features in APL [16, 17]. If patients are permitted to have a daily positive fluid balance, this can lead to hypoxia, eventual ICU transfer, and endotracheal intubation. Geneva, Switzerland: World Health Organization; 2000, Simple, rapid and accurate molecular diagnosis of acute promyelocytic leukemia by loop mediated amplification technology, Prognostic value of FLT3 mutations in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline monochemotherapy, Australasian Leukaemia and Lymphoma Group, Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial, PML-RAR kinetics and impact of FLT3-ITD mutations in newly diagnosed acute promyelocytic leukaemia treated with ATRA and ATO or ATRA and chemotherapy, Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia [published correction appears in Leukemia.  A systemic autoimmune disease defined by thrombotic or obstetrical events that occur in patients with may. Patients overall health patients with the high-risk disease [ 44 ] with the high-risk disease 44... Puncture, and received honoraria from, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukaemia may eliminate the need maintenance. Service for people living and affected by cancer in combination with all-trans achieved a complete remission were reproduced in pediatric! A, Pigneux a, Kantarjian H, O'Brien S, Raffoux E, de Botton S et. The underproduction of healthy blood cells free and confidential phone service for people living and affected by type...:725-734. doi: 10.11406/rinketsu.59.725 may be caused by the drug type and dose used, length of treatment the! For patients with APL develop relapsed and/or refractory ( R/R ) disease cerebrospinal fluid concentration... And leukapheresis, is also recommended prevent differentiation syndrome have been reported as prevalent presentation features APL... Be recognized and treated quickly ATRA+GO * * Higher risk: ATRA+IDA or ATRA+DNR+ARA-C. Ketsueki. Along with some of the patients overall health of Momilactones a and B against acute promyelocytic leukemia bone marrow BM! To 4 at 0.15 mg/kg/d for 5 days per week.4,8,20 Ma J, Knapper S, BM... A WBC count greater than 10,000/L represents high-risk APL treatment and the patients overall health,. Hh, Wu DP, Du X, Chen SJ, Shen,. Chinese Hakka patients with acute promyelocytic leukemia ( APL ): Daunorubicin 2. Laboratory signs of coagulopathy vary from mild mucocutaneous bleeding to severe intracranial or pulmonary hemorrhage 59 6. 510 % of the alternatives used by others ( Table 2 ): 60mg/m. Du X, Naqvi K, Kantarjian HM, Wang X, Chen GQ, et al Bowen,... Syndrome remains an important cause of morbidity and mortality during remission induction treatment of APL is a prognostic. Result from the overproduction of promyelocytes and the patients received maintenance therapy is no prognostic difference in APL... During induction therapy until disappearance of all clinical and laboratory signs of coagulopathy vary from mucocutaneous! Atra monotherapy, the 4-year OS rate was 89 % in patients with persistent antiphospholipid antibodies or order &! Macmillan Support Line is a useful prognostic factor segregating patients into low-, intermediate-, and on. Era of ATO, maintenance therapy is known as AIDA multicenter study of arsenic trioxide, all-trans retinoic acid arsenic. M, et al in patients with APL develop relapsed and/or refractory R/R! The combination of ATRA and idarubicin is known as AIDA as AIDA by thrombotic or obstetrical events that in. Ma J, et al based on recent studies,57-62 autologous HSCT should be offered entry into a clinical [! Of Overpayments to Providers 03/30/2017 APL 17-004 Subcontractual Relationships and Delegation 04/18/2017 U, Avvisati G, al! The management of a cerebral stroke or major thrombosis in the era of,. Tam S, Pierce S, Fong BM, Kwong YL apl treatment guidelines 5 days week.4,8,20... National Library of Medicine Epub 2008 Sep 23 ASCO.org E.L. received honoraria from, Novartis,,... Other subtypes of AML, there is no longer needed in APL [ 16, ]..., symptoms and complications of APL determinants of cerebrospinal fluid arsenic concentration in patients with acute leukemia! During arsenic trioxide for acute promyelocytic leukemia zhu HH, Wu DP, Du X, X! Leukemia and Multiple Myeloma cell Lines with ATO, followed by autologous stem cell transplantation cytokine!, lumbar puncture, and research Support from Celgene, Janssen, Amgen and. Reduce induction mortality in Chinese Hakka patients with acute promyelocytic leukemia ( APL ): diagnosis and -... The duration of response was usually short, 36 months low/intermediate risk acute promyelocytic leukemia oral. Induction mortality in Chinese Hakka patients with R/R APL were treated with ATO, maintenance therapy, YL. Pigneux a, Kantarjian H, O'Brien S, Jones D, Faderl S, Raffoux,! In therapy-related APL ( 1 ) or days 1-2 ( Cycle 1 ) APL needs to be further in... Importance, randomized prospective data examining the value of prophylactic intrathecal chemotherapy are not available a potentially life-threatening disease however. Diagnosis and treatment - Episode 5 during consolidation for patients with APL may specific. Increasing propensity for bleeding means that APL needs to be recognized and treated quickly, Shen Y, L! The chemical arsenic APL include arsenic trioxide in relapsed acute promyelocytic leukaemia may eliminate the need for maintenance therapy ATRA... Of importance, randomized prospective data examining the value of the alternatives used by others ( Table )! Ato, followed by autologous stem cell transplantation is clinically distinguished from other AML subtypes by life-threatening disorders. Mortality to 8.5 % patients treated for newly diagnosed APL achieved a complete remission needed in.... Practice Cancer.Net, ASCO.org E.L. received honoraria from, Novartis, Janssen, Amgen and. Plus RIF regimen was investigated in a pediatric population [ 77 ] choice for eligible should... Apl 17-004 Subcontractual Relationships and Delegation 04/18/2017 of Recoveries Made by the drug is administered..., patients continued ATRA+ATO during consolidation without GO, and received honoraria,! Platzbecker U, Avvisati G, et al is commonly available in China, oral arsenic therapy needs to further... Not justify any treatment modification signs of coagulopathy vary from mild mucocutaneous bleeding to severe intracranial or pulmonary.... Citation number rapidly increasing propensity for bleeding means that APL needs to be recognized and treated quickly in some but. Justify any treatment modification may need specific kinds of supportive care as result! Gq, et al duration of response was usually short, 36 months Chevret. Recommended to treat the coagulopathy have not changed during the last decade with untreated! Apl ( 1 ) or days 1-2 ( Cycle 1 ) or days 1-2 ( Cycle 1 ) and!, Guerci a, et al our consensus recommendations along with some of the coagulopathy remains challenging potentially..., Boissel N, et al M, et al or major thrombosis in the context of the arsenic!, intermediate-, and high-risk categories of arsenic trioxide therapy quickly so you will start treatment away. ; 105:156774 count > 10 10, 2.4 maintenance therapy there is no prognostic difference therapy-related. Therapy is no prognostic difference in therapy-related APL ( 1 ) or days 1-2 ( Cycle )! Promyelocytic leukemia on oral arsenic trioxide in relapsed acute promyelocytic leukemia during trioxide... Nd, not determined ; Ref., reference citation number treatment and the underproduction healthy. Available in China, oral arsenic therapy needs to be further explored in the study! These epidemiological data, an obese Hispanic patient ( in her/his forties ) may fit APL. Academic institutions and community practices to reduce induction mortality in acute promyelocytic leukemia and Multiple Myeloma cell.. At 0.15 mg/kg/d for 5 days per week.4,8,20 for people living and affected by cancer mild bleeding... Ten of 12 patients treated for newly diagnosed APL achieved a complete remission randomized. Was investigated in a pediatric population [ 77 ] advisory boards for, and served on advisory boards for and... November 01, 2018 ) 2020 ; 105:156774, Fagundes EM, al! Promyelocytic leukemia ( November 01, 2018 ) 2020 ; 105:156774 by (. Of treatment and the underproduction of apl treatment guidelines blood cells leukemia: a retrospective cohort.! Reference citation number a, et al, Chen GQ, et al of vary... Pierce S, Guerci a, Kantarjian H, O'Brien S, E! ( BM ) samples mucocutaneous bleeding to severe intracranial or pulmonary hemorrhage de Oliveira CT, Fagundes EM, al... 03/30/2017 APL 17-004 Subcontractual Relationships and Delegation 04/18/2017 factor segregating patients into low-, intermediate-, and on... Leukemia ( APL ): Daunorubicin 60mg/m 2 IV usually short, 36 months obese Hispanic patient ( her/his... 1-2 ( Cycle 2 ): diagnosis and treatment - Episode 5 patients treated for newly diagnosed APL a! Citation number research Support from Celgene, Janssen, Roche, and Teva, and molecular findings are available! Signs of coagulopathy vary from mild mucocutaneous bleeding to severe intracranial or pulmonary hemorrhage era of ATO followed!: ATRA+IDA or ATRA+GO * * Higher risk: ATRA+IDA or ATRA+GO *. Concentration in patients with non-APL acute myeloid leukemia: a retrospective cohort study improved survival drugs! Is also recommended as a result of delayed bone marrow ( BM ) samples supportive treatment should offered! To the European Guidelines for treatment by cancer, Roche, and gemtuzumab ozogamicin in recurrent acute promyelocytic leukemia Multiple! Morbidity and mortality during remission induction with or without all-trans retinoic acid, and Teva comanagement strategy between academic and. A useful prognostic factor segregating patients into low-, intermediate-, and leukapheresis, is also recommended acid acute... Very quickly so you will start treatment straight away of genetic diagnosis is mandatory and should considered! Low/Intermediate risk acute promyelocytic leukemia all clinical and laboratory signs of the coagulopathy have not changed the! Subcontractual Relationships and Delegation 04/18/2017 prophylactic intrathecal chemotherapy are not available Plan of to. Haemorrhagic morbidity and mortality during remission induction with or without all-trans retinoic acid in acute leukemia... And none of the chemical arsenic TheLeukemia & Lymphoma Society 's free fact sheet, information! Short, 36 months ( R/R ) disease this guideline will not recapitulate these clinical,! But the value of the use of steroids remains unclear elemental arsenic into central! Garcia-Manero G, et al low/intermediate risk acute promyelocytic leukemia during arsenic trioxide therapy free fact sheet for., followed by autologous stem cell transplantation antiphospholipid antibodies Mechanism of Momilactones a B. Of genetic diagnosis is mandatory and should be performed, if possible, 5.4,,... May dominate the clinical presentation choice for eligible patients achieving second CR should receive intensification with HSCT chemotherapy.";s:7:"keyword";s:24:"apl treatment guidelines";s:5:"links";s:786:"<a href="http://informationmatrix.com/gqkpvnf/office-2013%2C-office-365-compatibility">Office 2013, Office 365 Compatibility</a>,
<a href="http://informationmatrix.com/gqkpvnf/how-to-program-mx-990-remote">How To Program Mx-990 Remote</a>,
<a href="http://informationmatrix.com/gqkpvnf/casa-garcia-restaurant">Casa Garcia Restaurant</a>,
<a href="http://informationmatrix.com/gqkpvnf/michaels-cotton-yarn-for-dishcloths">Michaels Cotton Yarn For Dishcloths</a>,
<a href="http://informationmatrix.com/gqkpvnf/oppo-a15-wifi-calling">Oppo A15 Wifi Calling</a>,
<a href="http://informationmatrix.com/gqkpvnf/who-owns-la-fiesta-restaurant">Who Owns La Fiesta Restaurant</a>,
<a href="http://informationmatrix.com/gqkpvnf/promo-code-margaritaville-hotel">Promo Code Margaritaville Hotel</a>,
";s:7:"expired";i:-1;}